An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder.
Clinical neuropharmacology April 1, 2026 Jon E Grant, Sophia Boutouis, Margaret O'Brien et al.
A small open-label pilot study tested a single dose of psilocybin in nine adults aged 18 to 65 with both borderline personality disorder (BPD) and major depressive disorder (MDD). Depressive symptoms significantly improved from baseline to four weeks after dosing, with average scores dropping from 28.56 to 17.22. However, BPD symptoms did not show a significant change. The findings suggest that BPD may not interfere with psilocybin's effect on depressive symptoms, but larger clinical trials are needed.